Croatia

Pam Tadross is a Director of Engineering in the Merck Manufacturing Division (MMD). Beginning July 1, she will assume responsibility for the Las Piedras Operations (LPO) Site as the Pharmaceutical Technical Operations Lead for that site. Previously, Pam served as the Technical Product Steward for the commercial products Bridion,Molnupiravir, and Belsomra, leading the technical teams for each product focused on enabling the end-to-end technical elements of their strategic supply objectives. Additionally, as Group Leader for the Technical Product Stewards Team, Pam is accountable for a team of Stewards supporting a broad portfolio of products across several therapeutic areas. Prior to joining Technical Product Stewardship, Pam primarily supported commercialization, validation, and commercial manufacturing of active pharmaceutical ingredients (APIs) in MMD. Pam came to Merck through the acquisition of Cubist Pharmaceuticals, where she was a process development scientist for 1 week prior to the announcement of Merck’s acquisition of Cubist. Her pharmaceutical career with Cubist and Merck started in 2014 following completion of an NIH Postdoctoral Fellowship at Harvard University, focusing on asymmetric catalysis. Pam completed her Ph.D. in synthetic organic chemistry at Caltech in 2011, where she studied the exploitation of reactive aryne intermediates in natural product synthesis. In 2005, Pam received her B.S. in chemistry from NYU, where she also studied Latin. A native of Brooklyn, New York, Pam currently works in Puerto Rico and remotely from her home in Natick, Massachusetts, which she shares with her husband, Chris. In her free time, Pam enjoys landscape photography, knitting and sewing, cooking and baking, cross-country skiing, and traveling with her husband.